Form 4: Jazz Pharmaceuticals EVP Robert Iannone Reports Acquisition and Disposal of Ordinary Shares

EVP, Global Head of R&D at Jazz Pharmaceuticals, Robert Iannone, reports acquisition of 16,928 ordinary shares and disposal of shares on March 1, 2024.

Summary

• Robert Iannone, EVP, Global Head of R&D at Jazz Pharmaceuticals, filed a Form 4.
• The report details the acquisition of 16,928 ordinary shares on March 1, 2024, at a price of $0.0.
• Iannone also disposed of 66,520 ordinary shares.
• Following the reported transactions, Iannone beneficially owns a certain amount of ordinary shares.
• The filing also mentions restricted stock units granted under the 2011 Equity Incentive Plan, vesting annually over four years starting March 5, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, indicating neutral sentiment. It reports transactions by an insider, which doesn't inherently suggest positive or negative sentiment.

Positives

• The grant of restricted stock units indicates a continued investment in the company's leadership.

Future Outlook

The restricted stock units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Industry Context

Form 4 filings are standard practice for company insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of management's confidence in the company.

Key Dates